New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer

  • Study

    Single-arm, phase 2 trial (WSG-KEYRICHED-1, NCT03988036)
    Patients with HER2-positive early-stage (cT1c-T3/N0-1/M0) breast cancer
    Pembrolizumab + trastuzumab + pertuzumab for 12 wks

  • Efficacy

    pCR: 47% (null hypothesis not rejected)

  • Safety

    Grade ≥3 AEs: Hypersensitivity reaction, ALT increase, nephritis, panic attack


    • Lancet Oncol 2025;26: 629–40

    Kuemmel S,Graeser M,Schmid P Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

    http://doi.org/10.1016/S1470-2045(25)00097-X

    Reviewed by Ulas D. Bayraktar, MD on May 5, 2025

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag